Proteolytic processing of ErbB4 in breast cancer

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Hollmén, Maija ^a,b   Liu, Ping ^c   Kurppa, Kari ^a,b   Wildiers, Hans ^d   Reinvall, Irene ^a   Vandorpe, Thijs ^d   Smeets, Ann ^d   Deraedt, Karen ^d   Vahlberg, Tero ^e   Joensuu, Heikki ^f   Leahy, Daniel J ^c   Schöffski, Patrick ^d,g   Elenius, Klaus ^a,h  

^a UNIVERSITY OF TURKU   (Finland)

^b Turku Doctoral Programme of Biomedical Sciences   (Finland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF TURKU   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g Katholieke Universiteit   (Belgium)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1479; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BINDING SITE; BREAST CANCER; CONTROLLED STUDY; CRYSTALLIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

ADULT; ANTIBODIES, MONOCLONAL; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84862680728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039413     Document Type: Article

References (37)

1. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, et al. (2000) A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 275: 8641-8649.
2. Sepp-Lorenzino L, Eberhard I, Ma Z, Cho C, Serve H, et al. (1996) Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene 12: 1679-1687.
3. Ni CY, Murphy MP, Golde TE, Carpenter G, (2001) gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181.
4. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, et al. (2002) Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 277: 6318-6323.
5. Rio C, Buxbaum JD, Peschon JJ, Corfas G, (2000) Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275: 10379-10387.
6. Williams C, Allison J, Vidal G, Burow M, Beckman B, et al. (2004) The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 167: 469-478.
7. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, et al. (2006) Coregulation of Estrogen Receptor by ERBB4/HER4 Establishes a Growth-Promoting Autocrine Signal in Breast Tumor Cells. Cancer Res 66: 7991-7998.
8. Linggi B, Carpenter G, (2006) ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J Biol Chem 281: 25373-25380.
9. Sundvall M, Veikkolainen V, Kurppa K, Salah Z, Tvorogov D, et al. (2010) Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell 21: 4275-4286.
10. Sardi S, Murtie J, Koirala S, Patten B, Corfas G, (2006) Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 127: 185-197.
11. Ray WJ, Yao M, Mumm J, Schroeter EH, Saftig P, et al. (1999) Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J Biol Chem 274: 36801-36807.
12. Gao Y, Pimplikar SW, (2001) The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci U S A 98: 14979-14984.
13. McCarthy JV, Twomey C, Wujek P, (2009) Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci 66: 1534-1555.
14. Elenius K, Corfas G, Paul S, Choi CJ, Rio C, et al. (1997) A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 272: 26761-26768.
15. Muraoka-Cook R, Sandahl M, Strunk K, Miraglia L, Husted C, et al. (2009) ErbB4 splice variants Cyt1 and Cyt2 differ by sixteen amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol.
16. Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, et al. (2006) Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 17: 67-79.
17. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, et al. (2011) Function of ERBB4 is determined by alternative splicing. Cell Cycle 10: 2647-2657.
18. Zeng F, Zhang M, Singh A, Zent R, Harris R, (2007) ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. Mol Biol Cell 18: 4446-4456.
19. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, et al. (1999) Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 59: 5315-5322.
20. Hollmén M, Määttä J, Bald L, Sliwkowski M, Elenius K, (2009) Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 28: 1309-1319.
21. Srinivasan R, Gillett C, Barnes D, Gullick W, (2000) Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60: 1483-1487.
22. Hollmén M, Elenius K, (2010) Potential of ErbB4 antibodies for cancer therapy. Future Oncol 6: 37-53.
23. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, et al. (2005) Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65: 1384-1393.
24. Thor A, Edgerton S, Jones F, (2009) Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 175: 1802-1809.
25. Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, et al. (2009) Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Res Treat 115: 349-358.
26. Salfeld J, (2007) Isotype selection in antibody engineering. Nat Biotechnol 25: 1369-1372.
27. Cheng QC, Tikhomirov O, Zhou W, Carpenter G, (2003) Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem 278: 38421-38427.
28. Doedens J, Mahimkar R, Black R, (2003) TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. Biochem Biophys Res Commun 308: 331-338.
29. Bouyain S, Longo P, Li S, Ferguson K, Leahy D, (2005) The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A 102: 15024-15029.
30. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
31. Gardberg A, Dice L, Ou S, Rich R, Helmbrecht E, et al. (2007) Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A 104: 15659-15664.
32. Naresh A, Thor A, Edgerton S, Torkko K, Kumar R, et al. (2008) The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68: 6387-6395.
33. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ, (2000) Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60: 1483-1487.
34. Bacus S, Chin D, Yarden Y, Zelnick C, Stern D, (1996) Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148: 549-558.
35. Barnes N, Khavari S, Boland G, Cramer A, Knox W, et al. (2005) Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11: 2163-2168.
36. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, et al. (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25.
37. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi O, et al. (2008) Role of ErbB4 in Breast Cancer. J Mammary Gland Biol Neoplasia 13: 259-268.